The present disclosure relates to the use of a serine / threonine kinase inhibitor, particularly advantageous for quantifying BRAF proteins directly in a biological sample immobilized in formalin, by methods that can also be referred to as selective reaction monitoring (SRM) mass spectrometry or multiple reaction monitoring (MRM) From the threonine-protein kinase B-raf (BRAF), certain peptides and the ionization characteristics of the peptides are derived. The biological sample is chemically preserved and fixed, wherein the biological sample is selected from the group consisting of formalin-fixed tissue / cell, formalin-fixed / paraffin embedded tissue (FFPE) tissue / cell, FFPE tissue block and cells derived from the block, Tissue-cultured cells that are fixed and / or paraffin-embedded, as well as tissues and cells treated with formaldehyde containing formulation / fixative.
展开▼
